Intersect ENT Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT or view top-rated stocks.

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Intersect ENT saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 1,360,000 shares, a drop of 35.2% from the July 29th total of 2,100,000 shares. Based on an average daily volume of 743,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 4.3% of the shares of the company are sold short.
View Intersect ENT's Short Interest.

Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Intersect ENT.

Intersect ENT, Inc. (NASDAQ:XENT) announced its quarterly earnings data on Friday, August, 6th. The medical equipment provider reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.07. The medical equipment provider had revenue of $27.30 million for the quarter, compared to analyst estimates of $27.77 million. Intersect ENT had a negative trailing twelve-month return on equity of 102.23% and a negative net margin of 66.55%. The company's quarterly revenue was up 178.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.65) EPS.
View Intersect ENT's earnings history.

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 27.1% and is now trading at $27.32.
View which stocks have been most impacted by COVID-19.

Intersect ENT issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $117 million-$121 million, compared to the consensus revenue estimate of $119.79 million.

6 Wall Street analysts have issued 12 month price objectives for Intersect ENT's stock. Their forecasts range from $19.00 to $32.00. On average, they expect Intersect ENT's share price to reach $26.47 in the next year. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Intersect ENT or view top-rated stocks among Wall Street analysts.

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Intersect ENT include Haemonetics (HAE), AtriCure (ATRC), Axonics (AXNX), The Beauty Health (SKIN), NuVasive (NUVA), Glaukos (GKOS), Silk Road Medical (SILK), iRhythm Technologies (IRTC), Inovio Pharmaceuticals (INO), Treace Medical Concepts (TMCI), Cardiovascular Systems (CSII), Pulmonx (LUNG), Alphatec (ATEC), OrthoPediatrics (KIDS) and Sight Sciences (SGHT).
View all of XENT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Intersect ENT's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (13.43%), FMR LLC (10.45%), BlackRock Inc. (8.87%), First Light Asset Management LLC (6.64%), Vanguard Group Inc. (5.22%) and State Street Corp (3.02%). Company insiders that own Intersect ENT stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends for Intersect ENT.

XENT stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, JPMorgan Chase & Co., California Public Employees Retirement System, Goldman Sachs Group Inc., Russell Investments Group Ltd., Nuveen Asset Management LLC, Wells Fargo & Company MN, and Neuberger Berman Group LLC.
View insider buying and selling activity for Intersect ENT or view top insider-selling stocks.

XENT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, First Light Asset Management LLC, Millennium Management LLC, State Street Corp, Sei Investments Co., Grandeur Peak Global Advisors LLC, and Altium Capital Management LP. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT or or view top insider-buying stocks.

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENT stock can currently be purchased for approximately $27.32.

Intersect ENT has a market capitalization of $910.17 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72,320,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

Intersect ENT employs 406 workers across the globe.

The official website for Intersect ENT is www.intersectent.com.

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100 or via email at [email protected]